Side-effects of checkpoint inhibitor-based combination therapy.

Kourie HR, Klastersky JA

Curr Opin Oncol, (4):306-313 2016

MED: 27136134

PD-1/PD-L1 inhibitors.

Sunshine J, Taube JM

Curr Opin Pharmacol, 32-38 2015

MED: 26047524

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators, Kannourakis G, Steer C, Ganju V, O’Byrne K, Tafreshi A, Hui R, Burghuber O, Germonpre P, Lambrechts M, Robinson A, Smylie M, Hirsh V, Gervais R, Perol M, Bennouna J, Pouessel D, Reck M, Kopp G, Brossart P, Wehler TC, Spaeth-Schwalbe E, Molnar L, Balint B, Papai-Szekely Z, Csoszi T, Fulop A, Soter S, Szalai Z, Tehenes S, O’Reilly S, Coate L, Cuffe S, Gottfried M, Peled N, Wollner M, Bar Y, Ariad S, Merimsky O, Carteni G, Bidoli P, Gridelli C, Marchetti P, Tiseo M, Chiara Garassino M, Bonanno L, Grossi F, De Marinis F, Ardizzoni A, Horiike A, Satouchi M, Katakami N, Sekine A, Torii Y, Nakagawa K, Okamoto I, Maemondo M, Umemura S, Nosaki K, Saka H, Aoe K, Hotta K, Sakai H, Sugawara S, Takahashi T, Kishi K, Yamamoto N, de Langen J, Sullivan R, Garcia Campelo MG, Vidal OJ, Bernabe Caro R, Rubio Viqueira B, Domine Gomez M, Rodriguez-Abreu D, Felip E, Nicolson M, Lal R, Fennel DA, Potter V, Middleton G, O’Brien ME, Ottensmeir C, Califano R, Gandhi J, Tahsildar HI, Guarino MJ, Patel R, Dragnev K, Giaccone G, Rao S, Avery E, Sanborn R, Lawler WE, Konduri K, Robert F, Riess J, Garon EB, Leal TB, Morgensztern D, Ahuja H, Vanderwalde AM, Reichert SE, Bun PA Jr, Pirker R, Shih W

N Engl J Med, (19):1823-1833 2016

MED: 27718847

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB

Lancet, (10027):1540-1550 2015

MED: 26712084

Title not supplied

Socinski

Ann. Oncol., (6) 2016

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, [...] Spigel DR

N Engl J Med, (2):123-135 2015

MED: 26028407

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, [...] Brahmer JR

N Engl J Med, (17):1627-1639 2015

MED: 26412456

Title not supplied

AUTHOR UNKNOWN

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.

McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL

JAMA Oncol, (1):46-54 2016

MED: 26562159

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy.

Kleinovink JW, Marijt KA, Schoonderwoerd MJA, van Hall T, Ossendorp F, Fransen MF

Oncoimmunology, (4):e1294299 2017

MED: 28507803